JAMA Oncology 'Under Review': What Each Status Means and When to Expect a Decision

The status names and durations below are Manusights planning estimates. JAMA Oncology does not publish status definitions or stage durations, so confirm what your own portal shows.

Before the paper reaches external reviewers, one of the journal's editors evaluates whether the clinical-oncology significance warrants JAMA Oncology's selective editorial slots. With 3,738 submissions in 2025 and an 8 percent overall acceptance rate, most submissions are not accepted, and the journal reports a median of 3 days to first decision without external peer review. A desk rejection can mean the editor concluded that the work would fit better at a sister JAMA Network title (JAMA Network Open, JAMA) or that the broad-clinical-oncology audience appeal is uncertain.

The corresponding author receives an acknowledgment confirming receipt and a manuscript number. The package should already include the manuscript file (title page, Key Points, abstract, text, references, legends, and tables), figures (embedded at the end of the file or as separate files at initial submission), a cover letter, reporting checklists where applicable (CONSORT for clinical trials, PRISMA or MOOSE for meta-analyses, other EQUATOR checklists as they apply), a Data Sharing Statement, ethics approval or waiver for human-subjects research, and, for clinical trials, trial registration and the protocol with the complete statistical analysis plan. After submission, all authors receive a link to the Authorship Form.

An editor reads the paper and evaluates the criteria listed in the Instructions for Authors: originality and timeliness, clarity, appropriate methods, valid data, conclusions supported by the data, importance, and general interest to readers. This is the highest-risk point: many papers are rejected here without external review.

The journal does not publish a separate statistical-review stage with its own timing. Its masthead lists Associate Editors for Statistics, and its instructions say authors must cooperate fully in providing the data on which the manuscript is based if the editors ask for it. Statistical questions can therefore reach you with, or apart from, the external reviewer reports.

Manuscripts that pass the editorial read are sent to expert consultants for peer review. JAMA Oncology does not publish how many reviewers it invites or how long recruitment takes. As a planning estimate, recruiting topic-matched clinical-oncology reviewers can take one to two weeks, and finding qualified, available reviewers is often the biggest source of delay.

Once reviewers agree to review, the journal's 2025 year in review lists a median peer reviewer turnaround of 13 days, and extensions add to the total. The journal uses single-anonymized review: reviewers know who the authors are, and authors do not learn the reviewers' names unless a reviewer chooses to reveal them.

After reports return, the editors weigh them and decide. As a planning estimate this takes one to two weeks; JAMA Oncology does not publish a figure for this step. Final decisions are made by an editor who does not have a relevant conflict of interest.

• Rejection within 1 to 3 days: Typical of a desk rejection; the journal's median to first decision without external peer review is 3 days.

• Rejection within 1 to 3 weeks: Still most likely an editorial decision, though slower than the 3-day median.

• Still Under Review after 4 weeks: A positive sign. The paper likely went to external peer review (the journal's median to first decision with peer review is 32 days).

• Still Under Review after 10 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry via the submission portal is appropriate.

• Status changes to "Reports Received": Reports are in; expect a decision within 1 to 2 weeks.

This is the most common anxiety we hear from JAMA Oncology authors during the active editorial window. The honest answer: no. Six weeks is a little past the journal's published 32-day median to first decision with peer review, which most likely means your paper passed the editorial read and is in or just past external peer review.

Delays at this stage most often come from reviewer-recruitment timing for clinical-oncology specialists rather than slow reviews. If the portal still says Under Review at the 8-week mark, a likely explanation is that one of the assigned reviewers asked for an extension and the editor granted it.

During the 6-to-8-week window, the useful distinction is administrative versus scientific urgency. A short portal message is reasonable if you need to disclose a new trial-registration correction, ethics update, related publication, meeting embargo conflict, or material data error. A general "any update?" note is better held until week 8 because the most likely bottleneck is a reviewer extension or editorial deliberation, not a missing action from the author.

If your JAMA Oncology paper is rejected after review, the natural cascade depends on what the reviewers and deputy editor cited:

JAMA Network Open is the most natural JAMA Network cascade because authors can choose at submission to have a manuscript that is not accepted referred, with reviewers' comments if available, to a JAMA Network specialty journal or JAMA Network Open, preserving peer-review work. JAMA Network Open has a broader scope and an open-access publishing model.

Journal of Clinical Oncology (JCO) is the ASCO cascade option for clinical-oncology trial papers. ASCO operates independently; reports do not transfer, but JCO editors may recognize JAMA Network reviewer reports informally. JCO's review focus is similar but emphasizes ASCO-treatment-guideline implications.

Annals of Oncology is the ESMO cascade option for European-oncology-focused work. ESMO operates independently with its own reviewer pool.

Cancer Discovery (AACR) is a cascade option for translational-oncology papers where the basic-science mechanism is stronger than the clinical-trial focus. AACR operates independently from JAMA Network.

JAMA Oncology's Instructions for Authors list the criteria used to evaluate manuscripts: original and timely material, clear writing, appropriate study methods, valid data, reasonable conclusions supported by the data, important information, and general interest to the journal's readers. The table below maps four practical preparation areas to those criteria.

In our pre-submission work with JAMA Oncology manuscripts, three patterns generate the most consistent reviewer concerns we see at JAMA Oncology. The recurring issue is not only whether the trial, cohort, or oncology analysis is well run. It is whether the Key Points, first table, and statistical appendix let an editor and the reviewers see the same clinical decision without extra explanation.

CONSORT-compliance gaps surface as reviewer requests for clarification. When CONSORT checklist items are incomplete or trial-pre-registration alignment is unclear, reviewers consistently flag the manuscript for revision. The strongest revisions add complete CONSORT documentation with pre-registration alignment and explicit deviation explanations.

Check your JAMA Oncology reporting package →

Statistical analysis plan under-documented. When the pre-specified statistical analysis plan is thin or post-hoc analyses are not clearly distinguished from pre-specified analyses, reviewers consistently request expanded methods documentation. The strongest revisions add complete pre-specified analysis plans as supplementary material.

Check your statistical methods and SAP alignment →

Clinical-decision impact under-stated in framing. When the abstract and discussion do not clearly establish the clinical decision that would change, editors and reviewers flag general-clinical-interest concerns. The strongest manuscripts frame the abstract around the specific oncology decision the paper affects.

Check your oncology decision framing →

We have reviewed 50+ manuscripts targeting JAMA Oncology, Journal of Clinical Oncology, Annals of Oncology, Lancet Oncology, and JAMA Network Open. The JAMA Oncology misses tend to appear before the Methods section: the Key Points name an outcome but not the oncology decision, the abstract reports statistical significance without clinical actionability, or the first table makes subgroup balance and endpoint hierarchy harder to audit than it should be. Those are fixable before submission, and they matter because editors and reviewers read them before the methods.

In our pre-submission review work across clinical-oncology and general-medical targets, we see five recurring preventable risks: incomplete trial-registration alignment, weak explanation of post-hoc analyses, unclear clinical-decision framing, missing patient-flow or subgroup transparency, and related-paper disclosure that appears late instead of at upload. This is an internal Manusights review sample, not a JAMA Network outcome dataset, so we use it to identify preventable manuscript risks rather than to estimate acceptance probability.

Source limitation: official guidance explains JAMA Network author rules, timing signals, and reporting requirements, but it does not show private deputy-editor notes, statistical-review comments, or the reason a specific manuscript is still in the portal. That is why this page separates public status interpretation from manuscript-specific readiness signals.

Our strongest JAMA Oncology pre-submission fixes are usually small but consequential: rewrite the Key Points around the treatment, screening, diagnostic, survivorship, or policy decision; add a one-paragraph statistical-analysis audit to the cover letter; move SAP and checklist files into a clearly labeled supplementary package; and make the first response-template outline before reviewer reports arrive. Manusights does not train AI models on customer manuscripts; we do not train on private author files.

The 60-day money-back guarantee applies to eligible paid manuscript reviews. That combination lets authors pressure-test the paper without turning the manuscript into a public training artifact.

This page was created from JAMA Network's public author guidance at Jamanetwork author instructions, JAMA Network editorial-process documentation, JAMA Oncology's published submission and acceptance data (3,738 submissions and an 8 percent overall acceptance rate in 2025), and Manusights pre-submission review experience with JAMA Oncology-targeted manuscripts. The journal's medians come from its For Authors page and 2025 year in review; the stage windows on this page are Manusights planning estimates.

For the JAMA Network oncology landscape beyond JAMA Oncology, see JAMA Network Open (broader open-access), JAMA (top general-medicine), JAMA Internal Medicine (internal medicine focus), and sister oncology titles (JCO, Annals of Oncology, Lancet Oncology, Cancer Discovery).

The choice across these titles depends on whether the central contribution is top-clinical-oncology (JAMA Oncology), broad-clinical-medicine (JAMA), or specialty-oncology (JCO, Annals of Oncology). For technical issues during JAMA Network submission, the submission portal handles most queries via the manuscript record.

Preparing a response template that addresses both clinical and methodological perspectives accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the JAMA Oncology clinical-impact-plus-statistical-rigor bar before submission, our JAMA Oncology pre-submission diagnostic flags the CONSORT-compliance gaps and statistical-methodology weaknesses most likely to surface in reviewer reports.